Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of FDL169 Sublingual vs Oral in Healthy Subjects
NCT03424252Phase 1Completed
- Sponsor
- Flatley Discovery Lab
- Start
- Dec 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of FDL169 in cystic fibrosis (CF) (4 arms), sponsored by Flatley Discovery Lab. Primary endpoints: Maximum Plasma Concentration at 7 weeks, Time to Maximum Plasma Concentration at 7 weeks and 4 more. Started Dec 2017; status: completed.
02
Drugs
FDL169
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03424252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03424252.